» Articles » PMID: 30296959

Improvement of Gram-negative Susceptibility to Fluoroquinolones After Implementation of a Pre-authorization Policy for Fluoroquinolone Use: A Decade-long Experience

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Due to concerns over increasing fluoroquinolone (FQ) resistance among gram-negative organisms, our stewardship program implemented a preauthorization use policy. The goal of this study was to assess the relationship between hospital FQ use and antibiotic resistance.

Design: Retrospective cohort.

Setting: Large academic medical center.

Methods: We performed a retrospective analysis of FQ susceptibility of hospital isolates for 5 common gram-negative bacteria: Acinetobacter spp., Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Primary endpoint was the change of FQ susceptibility. A Poisson regression model was used to calculate the rate of change between the preintervention period (1998-2005) and the postimplementation period (2006-2016).

Results: Large rates of decline of FQ susceptibility began in 1998, particularly among P. aeruginosa, Acinetobacter spp., and E. cloacae. Our FQ restriction policy improved FQ use from 173 days of therapy (DOT) per 1,000 patient days to <60 DOT per 1,000 patient days. Fluoroquinolone susceptibility increased for Acinetobacter spp. (rate ratio [RR], 1.038; 95% confidence interval [CI], 1.005-1.072), E. cloacae (RR, 1.028; 95% CI, 1.013-1.044), and P. aeruginosa (RR, 1.013; 95% CI, 1.006-1.020). No significant change in susceptibility was detected for K. pneumoniae (RR, 1.002; 95% CI, 0.996-1.008), and the susceptibility for E. coli continued to decline, although the decline was not as steep (RR, 0.981; 95% CI, 0.975-0.987).

Conclusions: A stewardship-driven FQ restriction program stopped overall declining FQ susceptibility rates for all species except E. coli. For 3 species (ie, Acinetobacter spp, E. cloacae, and P. aeruginosa), susceptibility rates improved after implementation, and this improvement has been sustained over a 10-year period.

Citing Articles

A Baker's Dozen of Top Antimicrobial Stewardship Intervention Publications for Hospitalized Patients in 2021.

Marx A, Cluck D, Green S, Anderson D, Stover K, Chastain D Open Forum Infect Dis. 2022; 9(12):ofac600.

PMID: 36519115 PMC: 9732520. DOI: 10.1093/ofid/ofac600.


Evaluation of Susceptibility Patterns in Uropathogens and Empiric Antibiotic Therapy in the Emergency Department.

Koro M, Borgert S, Abbott A, Venugopalan V Hosp Pharm. 2021; 56(6):745-750.

PMID: 34732933 PMC: 8559053. DOI: 10.1177/0018578720957965.


Guidelines on Implementing Antimicrobial Stewardship Programs in Korea.

Yoon Y, Kwon K, Jeong S, Moon C, Kim B, Kiem S Infect Chemother. 2021; 53(3):617-659.

PMID: 34623784 PMC: 8511380. DOI: 10.3947/ic.2021.0098.


Restriction-free antimicrobial stewardship initiative targeting fluoroquinolone reduction across a regional health-system.

Chin J, Green S, McKamey L, Gooch M, Chapin R, Gould A Infect Prev Pract. 2021; 1(2):100019.

PMID: 34368680 PMC: 8335920. DOI: 10.1016/j.infpip.2019.100019.


Association between fluoroquinolone utilization rates and susceptibilities of gram-negative bacilli: Results from an 8-year intervention by an antibiotic stewardship program in an inner-city United States hospital.

Zeana C, Palmieri F, Gupta V, Ye G, Lao P, Yu K Sci Prog. 2021; 104(2):368504211011876.

PMID: 33908291 PMC: 10455014. DOI: 10.1177/00368504211011876.